Patents by Inventor Markus Gude

Markus Gude has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazole-proline derivatives
    Patent number: 11040966
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: June 22, 2021
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20190263797
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi Williams
  • Benzimidazole-proline derivatives
    Patent number: 10329287
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 25, 2019
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
    Patent number: 10023560
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 17, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Use of benzimidazole-proline derivatives
    Patent number: 9914721
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Catherine Roch, Christine Brotschi, Markus Gude, Bibia Heidmann, Francois Jenck, Thierry Sifferlen, Michel Steiner, Jodi T. Williams
  • Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
    Patent number: 9914720
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: March 13, 2018
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST
    Publication number: 20180002317
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 4, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS
  • BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20170305897
    Abstract: The present invention relates to compounds of the formula (II) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (II), and especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. Williams
  • Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
    Patent number: 9790208
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: October 17, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Markus Von Raumer, Jodi T. Williams
  • Benzimidazole-proline derivatives
    Patent number: 9732075
    Abstract: The present invention relates to compounds of the formula (I) wherein Ar1, R1, R2, R3, R4a, R4b and (R5)n are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: August 15, 2017
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi Williams
  • USE OF BENZIMIDAZOLE-PROLINE DERIVATIVES
    Publication number: 20170001985
    Abstract: The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: December 3, 2014
    Publication date: January 5, 2017
    Inventors: Christoph BOSS, Catherine ROCH, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Francois JENCK, Thierry SIFFERLEN, Michel STEINER, Jodi T. WILLIAMS
  • CRYSTALLINE FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1 -YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AND ITS USE AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20160368901
    Abstract: The invention relates to crystalline forms of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone, processes for the preparation thereof, pharmaceutical compositions containing such crystalline forms, pharmaceutical compositions prepared from such crystalline forms, and their use as a medicament, especially as orexin receptor antagonists.
    Type: Application
    Filed: December 2, 2014
    Publication date: December 22, 2016
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS
  • CRYSTALLINE SALT FORM OF (S)-(2-(6-CHLORO-7-METHYL-1H-BENZO[D]IMIDAZOL-2-YL)-2-METHYLPYRROLIDIN-1-YL)(5-METHOXY-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)METHANONE AS OREXIN RECEPTOR ANTAGONIST
    Publication number: 20160355506
    Abstract: The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.
    Type: Application
    Filed: December 2, 2014
    Publication date: December 8, 2016
    Inventors: Christoph BOSS, Christine BROTSCHI, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Markus VON RAUMER, Jodi T. WILLIAMS
  • Orexin receptor antagonists which are [bi-(hetero-)aryl]-[2-(bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
    Patent number: 9493446
    Abstract: The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: November 15, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives
    Patent number: 9428456
    Abstract: The present invention relates to 1-[m-carboxamido(hetero)aryl-methyl]-heterocycyl-carboxamide compounds of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5a, R5b and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: August 30, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Markus Gude, Philippe Guerry, Thierry Kimmerlin, Francois Lehembre, Thomas Pfeifer, Anja Valdenaire
  • Pyrazole and imidazole derivatives useful as orexin antagonists
    Patent number: 9303023
    Abstract: The present invention relates to pyrazole and imidazole derivatives of formula (I) wherein U, V, L, X, Y, R1, (R2)n and (R3)m and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: April 5, 2016
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • Proline sulfonamide derivatives as orexin receptor antagonists
    Patent number: 9211279
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I) wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: December 15, 2015
    Assignee: ACTELION PHARMACEUTICALS LTD.
    Inventors: Christoph Boss, Christine Brotschi, John Gatfield, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • 1-[m-Carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide Derivatives
    Publication number: 20150336893
    Abstract: The present invention relates to 1-[m-carboxamido(hetero)aryl-methyl]-heterocycyl-carboxamide compounds of formula (I) wherein X, Ar1, R1, R2, R3, R4, R5a, R5b and p are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
    Type: Application
    Filed: June 21, 2013
    Publication date: November 26, 2015
    Inventors: Heinz FRETZ, Markus GUDE, Philippe GUERRY, Thierry KIMMERLIN, Francois LEHEMBRE, Thomas PFEIFER, Anja VALDENAIRE
  • OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
    Publication number: 20150252032
    Abstract: The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.
    Type: Application
    Filed: October 9, 2013
    Publication date: September 10, 2015
    Inventors: Martin Bolli, Christoph Boss, Christine Brotschi, Markus Gude, Bibia Heidmann, Thierry Sifferlen, Jodi T. Williams
  • PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
    Publication number: 20150246021
    Abstract: The present invention relates to (S)-proline sulfonamide compounds of formula (I), wherein R1 and R2 are as described in the description, or pharmaceutically acceptable salts thereof, for use in the prevention or treatment of diseases or disorders related to the orexin system. The present invention also relates to the use of (S)-proline sulfonamide compounds of formula (II) as pharmaceuticals, to pharmaceutical compositions comprising compounds of formula (II), and especially their use in the prevention or treatment of diseases or disorders related to the orexin system.
    Type: Application
    Filed: March 5, 2015
    Publication date: September 3, 2015
    Inventors: Christoph BOSS, Christine BROTSCHI, John GATFIELD, Markus GUDE, Bibia HEIDMANN, Thierry SIFFERLEN, Jodi T. WILLIAMS